$LIVN

LivaNova PLC (LIVN) reported that a 36-month study of its VNS Therapy for Drug-Resistant Epilepsy showed a 73% reduction in seizure-related hospitalizations, improved quality of life, and sustained benefits. The CORE-VNS study, published in Neuromodulation, involved 531 participants across 16 countries, with 426 completing follow-up. The company highlights the therapy's long-term effectiveness and safety.

Bianchi Francesco sold 3,500 shares of LivaNova PLC (LIVN) at $78.01 ($0.27M total) on 2026-09-10.

Story Brooke sold 2,300 shares of LivaNova PLC (LIVN) at $81.42 ($0.19M total) on 2026-09-04.

Bianchi Francesco sold 1,650 shares of LivaNova PLC (LIVN) at $79.72 ($0.13M total) on 2026-08-31.

LivaNova PLC (LIVN) officer Francesco Bianchi plans to sell 1,650 shares of common stock under Rule 144, valued at $131,538. The shares stem from vested restricted stock units awarded in 2023 and 2024. Bianchi also sold 1,800 shares in May 2026 and 1,200 shares in June 2026.

Tezel Ahmet (Chief Innovation Officer) sold 2,675 shares of LivaNova PLC (LIVN) at $77.74 ($0.21M total) on 2026-08-11.

Tezel Ahmet (Chief Innovation Officer) sold (to issuer) 8,589 shares of LivaNova PLC (LIVN) at $77.86 ($0.67M total) on 2026-08-11.

LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.